SGRY

Rating buyAI Memo

Surgery Partners

As of 2026-09-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

6‑12m

Key catalyst

Idaho Falls divestiture completion • 2026-12-16

Base target: $17 / p=50% prob

Biggest risk

Q2 adjusted EBITDA declined despite revenue growth, while same-facility case growth was only 0.3%. That divergence raises the risk that reimbursement mix, costs or weak volume prevent higher-acuity revenue from translating into stronger earnings and cash flow. The divestiture also remains conditional. [#SEC-8K-2026-08-10]

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Same-facility revenue growth, higher revenue per case, reaffirmed guidance and portfolio optimization provide a credible path to EBITDA stabilization, improved cash conversion and deleveraging. Director Teresa DeLuca's August 18 open-market purchases totaling 21,250 shares provide a modest alignment signal, not proof of operating improvement. [#SEC-8K-2026-08-10] [#SEC-FORM4-2026-08-19] [#SEC-FORM4-2026-08-20]

Research note

Recommendation

buy

Confidence

medium

As of

2026-09-17

Base target

$17

p=50%

Bull target

$20

p=30%

Bear target

$10

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Guidance delivery and EBITDA stabilization
Higher-acuity ASC growth and cash conversion
Same-facility revenue growth, higher revenue per case, reaffirmed guidance and portfolio optimization provide a credible path to EBITDA stabilization, improved cash conversion and deleveraging.

BearKey bullets

Adjusted EBITDA fell to $125.2 million from $129.0 million even as quarterly revenue increased, indicating unresolved margin or cost pressure.
[#SEC-8K-2026-08-10]
Greater government reimbursement exposure could pressure margins and valuation if payer mix deteriorates.

WatchKey bullets

Idaho Falls divestiture completion

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $17 (p=50%)

Target spread vs base: +21% / -39%

Scenario probabilities

Bull Target: $20 (p=30%)Base Target: $17 (p=50%)Bear Target: $10 (p=20%)

Commentary

Primary-source tone is cautiously constructive: management reaffirmed FY2026 guidance and emphasized portfolio optimization, but weak case growth and lower adjusted EBITDA temper the message. The director purchases are modestly supportive but cannot substitute for operating evidence. Social coverage is unavailable, and options skew, short interest, employee sentiment, confirmed post-release price reaction and post-Q2 analyst revisions were not supplied; the zero sentiment fields denote unavailable data rather than neutral readings. This remains a moderate-conviction monitoring view.

As of 2026-09-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Guidance delivery and EBITDA stabilization
Higher-acuity ASC growth and cash conversion

Scenarios

Bull Target (Scenario probability)

$20 / p=30% prob

Base Target (Scenario probability)

$17 / p=50% prob

Bear Target (Scenario probability)

$10 / p=20% prob

Analysis 2026-09-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-16
Idaho Falls divestiture completion
Management said the pending Idaho Falls transaction should improve cash conversion and support deleveraging, but closing remains subject to physician-member and governing-board approvals. Completion on attractive terms would strengthen the balance-sheet narrative; delay or changed terms would weaken it. [#SEC-8K-2026-08-10]
Prob 55.00% • Move 9.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Guidance delivery and EBITDA stabilization
2026-12-16
Q2 revenue increased 2.7% and same-facility revenue increased 5.0%, driven primarily by 4.8% higher revenue per case, but same-facility cases rose only 0.3% and adjusted EBITDA declined to $125.2 million from $129.0 million. Delivery against reaffirmed FY2026 revenue guidance of $3.35-$3.45 billion and adjusted EBITDA of at least $530 million is the principal near-term test. [#SEC-8K-2026-08-10] [#8-K-2026-08-10]
Prob 58% • Move 12% • Priced-in 50%

Long-term Catalysts

Months to a year

Higher-acuity ASC growth and cash conversion
2027-09-17
Management identifies structural ambulatory-surgery-center growth, higher-acuity procedures, operating efficiency and disciplined capital deployment as long-term drivers. The thesis requires stronger procedure growth and conversion of revenue-per-case gains into EBITDA and cash flow, rather than continued reliance on pricing or mix. [#SEC-8K-2026-08-10]
Prob 60% • Move 20% • Priced-in 45%

Risks

Adjusted EBITDA fell to $125.2 million from $129.0 million even as quarterly revenue increased, indicating unresolved margin or cost pressure. [#SEC-8K-2026-08-10]
Greater government reimbursement exposure could pressure margins and valuation if payer mix deteriorates.
SGRY reported a $15.0 million attributable net loss in Q2, while leverage and cash-flow execution remain important constraints on equity upside. [#SEC-8K-2026-08-10]
Same-facility case growth of only 0.3% leaves current growth dependent largely on revenue per case and procedure mix. [#SEC-8K-2026-08-10]
The Idaho Falls transaction remains subject to closing conditions, so anticipated cash-conversion and deleveraging benefits are not assured. [#SEC-8K-2026-08-10]

Peers

Symbol	Summary
HCA	A much larger hospital and ambulatory operator that provides useful procedure-volume and payer-mix context, but its scale and business mix make valuation comparisons imperfect.
THC	Tenet's USPI business offers a more relevant ambulatory-surgery comparison, although Tenet remains materially larger and includes businesses outside SGRY's focused short-stay platform.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-17

Loading AI feed…

Symbol

Summary

HCA

A much larger hospital and ambulatory operator that provides useful procedure-volume and payer-mix context, but its scale and business mix make valuation comparisons imperfect.

THC

Tenet's USPI business offers a more relevant ambulatory-surgery comparison, although Tenet remains materially larger and includes businesses outside SGRY's focused short-stay platform.